加科思-B(01167.HK):完成泛KRAS抑制劑JAB-23E73 I/IIa期臨牀試驗在中國的首例患者給藥
格隆匯11月25日丨加科思-B(01167.HK)發佈公吿,公司自主研發的泛KRAS抑制劑 JAB-23E73在中國完成I/IIa期臨牀試驗首例患者給藥。KRAS廣泛存在於多種腫瘤突變,約23%-25%的癌症患者帶有KRAS突變,全球每年新增約270萬帶有KRAS相關突變的腫瘤患者有望從泛KRAS抑制劑中獲益。
JAB-23E73可同時抑制KRAS的活性及非活性狀態的KRAS,並對HRAS、NRAS 無明顯抑制。作為口服KRAS抑制劑,JAB-23E73的臨牀前資料展現了良好的藥代動力學特性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.